Mid-Day Market Update: Nasdaq Rises 150 Points; NCR Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 300 points on Wednesday.
Why Molecular Partners Shares Are Getting Hammered
Molecular Partners AG (NASDAQ: MOLN) shares are trading lower by 36.52% at $8.38 after the company and its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours.
Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen
Molecular Partners AG’s (NASDAQ:MOLN) collaborating partner Amgen Inc (NASDAQ:AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners…
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data
Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate…
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours:
21 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 36.2% to $0.2675 in pre-market trading. Baudax Bio, last month, announced a $4.2 million registered direct offering.